Τόμος 25 (2007) – Τεύχος 2+3 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 25 (2007) – Issue 2+3– Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Μαρία Μυρωνίδου-Τζουβελέκη και Χαράλαμπος Δόκος

Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Maria Mironidou-Tzouveleki and Charalampos Dokos

Department of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

2. Shepherd J.: Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes? Athero­sclerosis (Supplement 6: 15-19 (2005)

3. Bell S.H. D.: A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid de­rivative, in the treatment of patients with diabetic dyslipi­demia. Clin. Ther. 17: 901-910 (1995)

4. Cohn G., Valdes G., Capuzzi D.M.: Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr. Cardiol. Rep. 3): 416-423 (2001)

5. El-Swefy S., Schaefer E.J., Seman L.J., Van Dongen D., Sevanian A., Smith D.E., Ordovas J.M., El-Sweidy M., Mey­dani M.: The effect of vitamin E, prubocol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipi­demic-diabetic hamsters. Atherosclerosis 14: 277-286 (2000)

6. Fuster V., Alexander W.R., O’Rourke A.R.: Hurt’s: The Heart. Volume I, 10^th edition. Chapter 38, pp.1135-1140, McGraw-Hill, 2000

7. Ferro A.: The endothelium made easy – from basic science to clinical applications. Elsevier Canada, 2003

8. Ding H., Hashem M., Wiehler B.W., Lau W., Martin J., Reid J., Triggle C.: Endothelial dysfunction in the strepto­zotocin-induced diabetic apoE-deficient mouse. Br. J. Pharm 146: 1110-1118 (2005)

9. Mandalos A., Mavracanas T., Zanos S., Miltsios C., Bolomitis S., Mironidou-Tzouveleki M.: New findings on nitrogen monoxide research: from physiology to the clini­cal practice. Epitheor. Klin. Farmakol. Farma­cokinet. (Greek Edition) 19: 5-24 (2001)

10. Tenenbaum A., Fisman E.Z.: Impaired glucose me­tabolism in patients with heart failure: pathophysiology and possible treatment strategies. Am. J. Cardiovasc. Drugs 4: 269-280 (2004)

11. Mulder H., Yang S., Winzell S.M., Holm C., Ahren B.: Inhibition of lipase activity and lipolysis in rat islets re­duces insulin secretion. Diabetes 53: 122-128 (2004)

12. Raz I., Eldor R., Cernea S., Shafrir E.: Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabe­tes Metab. Res. Rev. 21: 3-14 (2005)

13. Ellsworth J.A., Witt M.D., Dugdale C.D., Oliver M.L.: Mosby’s 2006 Medical Drug Reference. Pp. 586-588, 741-742, Elsevier Mosby, Philadelphia, 2006

14. Greek National Formulary. P. 152, Athens, 2003

15. Lovastatin (Mevacor). Merck & co, Inc, 2005

16. Asberg A.: Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant patients. Drugs 63: 367-378 (2003)

17. Orlistat (Χenical). Roche pharma­ceutical company, 2002

18. Nelson H.R., Miles M.J.: The use of orlistat in the treat­ment of obesity, dyslipidaemia and type 2 diabetes. Exp. Opin. Pharmacother. 6: 2483-2491 (2005)

19. Ueshima K., Akihisa-Umeno H., Nagayoshi A., Taka­kura S., Matsuo M., Mutoh S.: A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet. EJP 501: 137-142 (2004)

20. Boulogne A., Vantyghem M.C.: Treatments principles for the metabolic syndrome. Presse Méd. 33: 673-81 (2004)

21. Liberopoulos E.N., Tsouli S., Mikhailidis D.P., Elisaf M.S.: Preventing type 2 diabetes in high risk patients: an over­view of lifestyle and pharmacological measures. Curr. Drug Targets 7: 211-228 (2006)

22. Chapman J.M.: Therapeutic elevation of HDL-choles­terol to prevent atherosclerosis and coronary heart dis­eases. Pharmacol. Therapeut. 11: 893-908 (2006)

23. Tenenbaum A., Fisman Z.E.: Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statin or both? Cardiovasc. Diabetol. 3: 10 (2004)

24. Derosa G., Mugellini A., Ciccarelli L., Rinaldi A, Fo­gari R.: Effects of orlistat, simvastatin, orl­istat+simvastatin in obese patients with hypercholes­terolemia: a randomized, open-label trial. Curr. Ther. Res. Clin. Exp. 63: 621-633 (2002)

25. Bliznakov G.E.: Diabetes and the role of isoprenoid biosynthesis. FEBS Letters 525: 169-170 (2002)

26. Simonen P.P., Gylling H., Miettinen A.T.: Diabetes and cholesterol metabolism. Diabetes Care 26: 550 (2003)

27. Berg M.J., Tymoczko L.J., Stryer L.: Biochemistry. 5^th Edition, W.H Freeman and Company, 2002